Biotech company shares jumped 46% in $300m Hong Kong debut
Biotech firm Insilico Medicine leverages artificial intelligence for drug discovery. “We want to convert our customer base not only from pharma to other companies, but we also want to make large language model companies more intelligent,” its founder says. (Insilico Medicine)
LORRETTA CHEN
December 31, 2025 12:20 JST
HONG KONG — Buoyed by a strong stock market debut, Insilico Medicine, a biotech company leveraging artificial intelligence for drug discovery, said it is aiming to shift its customer base from pharmaceutical companies to other AI-focused firms to drive growth.